The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal liver metastasis (CRLM) patients with positive ctDNA after surgery is superior with the combination of adjuvant chemotherapy and maintenance therapy compared to adjuvant chemotherapy alone.
Both males and females, aged 18-75 years;
Patients with liver metastatic colorectal cancer who have undergone R0 resection based on MDT evaluation (including patients whose metastases have been treated with ablation achieving similar R0 resection effect);
Postoperative ctDNA-positive patients;
ASA grade < IV and/or ECOG performance status score ≤ 2;
Patients with distant metastases to other sites, including the pelvis, ovaries, peritoneum, etc.
Patients with a history of other malignant tumors.
Patients with severe liver or kidney dysfunction, cardiorespiratory dysfunction, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy.
Patients who are allergic to any component of the study.